98%
921
2 minutes
20
Extrahepatic recurrence (EHR) after curative hepatectomy for hepatocellular carcinoma (HCC) is associated with a poor prognosis. We investigated the features of EHR and identified its predictive factors. This retrospective study included 398 treatment-naive patients who underwent curative hepatectomy for HCC at two tertiary hospitals. Multivariate Cox-regression analysis was performed to identify the variables associated with EHR. EHR was diagnosed in 94 patients (23.6%) over a median follow-up period of 5.92 years, most commonly in the lungs (42.6%). The 5-/10-year cumulative rates of HCC recurrence and EHR were 63.0%/75.6% and 18.1%/35.0%, respectively. The median time to EHR was 2.06 years. Intrahepatic HCC recurrence was not observed in 38.3% of patients on EHR diagnosis. On multivariate analysis, pathologic modified Union for International Cancer Control stage (III, IVa), surgical margin involvement, tumor necrosis, sum of tumor size > 7 cm, and macrovascular invasion were predictive factors of EHR. Four risk levels and their respective EHR rates were defined as follows: very low risk, 1-/5-year, 3.1%/11.6%; low risk, 1-/5-year, 12.0%/27.7%; intermediate risk, 1-/5-year, 36.3%/60.9%; and high risk, 1-year, 100.0%. Our predictive model clarifies the clinical course of EHR and could improve the follow-up strategy to improve outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217564 | PMC |
http://dx.doi.org/10.1038/s41598-021-92503-6 | DOI Listing |
Eur J Surg Oncol
July 2025
General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, PISA, Italy.
Introduction: Surgery for resectable gallbladder cancer (GbC) encompasses complex operative management, and evaluating surgical quality through textbook outcome (TO) is crucial. This study aimed to assess TO incidence and impact in a global cohort, identify independent predictors, and evaluate TO rates of minimally invasive (MI) techniques, including robotic (ROB) and laparoscopic (LPS).
Materials And Methods: This cohort study included patients undergoing curative-intent hepatectomy and lymphadenectomy for GbC (T1b-T3) from 2012 to 2023 in 41 hospitals.
Surg Oncol
September 2025
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Background: The extent of primary hepatectomy for hepatocellular carcinoma (HCC) may influence long-term outcomes, especially at recurrence. We investigated whether initial minor or major hepatectomy impacts retreatment options and survival following recurrence.
Methods: We retrospectively reviewed patients with primary HCC who underwent either initial major or minor hepatectomy.
HPB (Oxford)
August 2025
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Electronic address:
Background: No validated model incorporates surgical parameters for complication risk in hepatocellular carcinoma (HCC) resection. We evaluated a novel Surgical Burden Score (SBS), integrating adjusted blood loss (aBL; mL/kg) and operative time (hours) via a Pythagorean formula, and developed an SBS-based model to predict complications.
Methods: Patients undergoing curative-intent hepatectomy for HCC(2000-2023) were identified from an international database.
PLoS Negl Trop Dis
September 2025
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Background: Hepatocellular carcinoma (HCC) prognosis is poor in East Asia. The impact of Clonorchis sinensis (C.sinensis) infection, a known carcinogen for cholangiocarcinoma, on HCC prognosis after curative resection in co-endemic regions is unclear.
View Article and Find Full Text PDFGlob Health Med
August 2025
National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Liver resection (LR) remains a cornerstone curative option for patients with hepatocellular carcinoma (HCC), and yet the high rate of postoperative intrahepatic recurrence poses a significant clinical challenge. Despite numerous attempts, no adjuvant therapy has shown definitive efficacy in preventing recurrence. In this context, salvage liver transplantation (SLT) and repeat hepatectomy (RH) have emerged as key curative strategies for recurrent disease.
View Article and Find Full Text PDF